Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prior exposure to advanced therapy and timing of discontinuation and risk of serious infections in patients with inflammatory bowel disease initiating a new advanced therapy.

Journal of Crohn's & colitis·2026
Same author

The impact of normalization of histology on disease course in microscopic colitis: a retrospective cohort study.

Inflammatory bowel diseases·2026
Same author

Impact of advanced therapy initiation on antibiotic dependence in chronic pouchitis.

Inflammatory bowel diseases·2026
Same author

Inflammatory bowel disease phenotypes in diverse populations: a global comparative analysis.

Journal of Crohn's & colitis·2026
Same author

Microbiome-Directed Therapy for Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Placebo-Controlled Trial of Multistrain Probiotic Supplementation.

The American journal of gastroenterology·2026
Same author

Fecal Calprotectin as a Biomarker for Disease Activity in Microscopic Colitis.

Journal of clinical gastroenterology·2026
Same journal

Anti-fibrotic therapy in Crohn's disease: hype or reality-can intestinal fibrosis be targeted effectively?

Expert review of gastroenterology & hepatology·2026
Same journal

Management of gastric varices: treatment options and opportunities to improve outcomes.

Expert review of gastroenterology & hepatology·2026
Same journal

Microbial ecology and hepatocellular carcinoma: should a subset be viewed as a microbiome-conditioned malignancy?

Expert review of gastroenterology & hepatology·2026
Same journal

FAPI PET in inflammatory bowel disease: a novel window on fibroblast activity, with unanswered clinical questions.

Expert review of gastroenterology & hepatology·2026
Same journal

Lyon Consensus 2.0: what has changed for GERD diagnosis?

Expert review of gastroenterology & hepatology·2026
Same journal

Proton pump inhibitors in children: indications and safety.

Expert review of gastroenterology & hepatology·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Personalizing therapy for inflammatory bowel diseases.

Ashwin N Ananthakrishnan1

  • 1Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, 165 Cambridge Street, 9th Floor, Boston, MA 02114, USA. aananthakrishnan@partners.org

Expert Review of Gastroenterology & Hepatology
|August 30, 2013
PubMed
Summary
This summary is machine-generated.

Inflammatory bowel diseases (IBD) management requires personalized treatment algorithms. Tailoring therapies to individual disease progression and treatment response is crucial for better outcomes in Crohn's disease and ulcerative colitis patients.

More Related Videos

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Related Experiment Videos

Last Updated: May 8, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Area of Science:

  • Gastroenterology and Immunology
  • Chronic Disease Management

Background:

  • Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic immune-mediated conditions.
  • IBD is characterized by unpredictable relapses, leading to significant bowel damage, functional impairment, hospitalization, and surgery.
  • While new therapies improve remission rates, their high cost and side effects limit accessibility and widespread use.

Purpose of the Study:

  • To highlight the need for personalized management algorithms in IBD.
  • To emphasize incorporating individual disease trajectories and treatment response probabilities into therapeutic decisions.
  • To address the challenge of managing treatment non-response in IBD patients.

Main Methods:

  • Review of current therapeutic strategies and their limitations in IBD.
  • Analysis of factors influencing disease progression and treatment outcomes.
  • Conceptual framework for personalized IBD management algorithms.

Main Results:

  • Significant heterogeneity exists in the natural history of IBD.
  • Current advanced therapies offer improved remission but face barriers related to cost and side effects.
  • A personalized approach is essential for optimizing IBD care.

Conclusions:

  • Personalized management algorithms are necessary for effective IBD treatment.
  • Integrating patient-specific factors like disease progression and treatment response is key.
  • Optimizing the management of treatment loss of response is critical for long-term patient well-being.